Oct 29 (Reuters) -
IMMUNO BIOLOGICAL LABORATORIES CO LTD
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Full year to Full year ended
Sep 30, 2010 Sep 30, 2009 Mar 31, 2011 Mar 31, 2010
LATEST YEAR-AGO COMPANY YEAR-AGO
H1 RESULTS H1 RESULTS FORECAST RESULTS Sales 498 mln 448 mln 1.02
(+11.1 pct) (-14.7 pct) (-3.7%) Operating loss 119 mln loss 173 mln loss 160 mln Recurring loss 114 mln loss 171 mln loss 155 mln Net loss 121 mln loss 171 mln loss 195 mln EPS loss Y196.52 loss Y277.77 loss Y316.36 Shares 616,400 616,400 Annual div nil nil -Q2 div nil nil -Q4 div nil nil
NOTE - Immuno Biological Laboratories Co Ltd is the full company name.
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half dividend and Q4 to the second-half dividend announced before a new corporate law in 2006 allowed companies to pay and report dividends on a quarterly basis.
For latest earnings estimates made by Toyo Keizai, please double click on.
Our Standards: The Thomson Reuters Trust Principles.